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Medication-Related Osteonecrosis 
of the Jaw: An Overview
Marko Blašković and Dorotea Blašković
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is a rare side effect of 
medications belonging to the antiresorptive (AR) and antiangiogenic (AA) groups. 
The first cases were described in the literature in 2003, and more than 1300 publica-
tions and 15,000 cases have been published since then. The incidence of MRONJ 
among cancer patients treated with bisphosphonates is 0–6.7%, with denosumab 
is 0.7–1.7% and with bevacizumab is 0.2%. Patients treated for osteoporosis have 
a lower risk of developing MRONJ at 0.02 and 0.04% with bisphosphonates and 
0.2% with denosumab. In more than 50% of cases, tooth extraction was considered 
the causative factor responsible for the onset of the MRONJ. Treatment strategies 
include preventive, medical and surgical interventions.
Keywords: medication-related osteonecrosis of the jaw, bisphosphonate-related 
osteonecrosis of the jaw, antiresorptive-associated osteonecrosis of the jaw, 
denosumab, antiangiogenic medicamentations
1. Introduction
Medication-related osteonecrosis of the jaw (MRONJ) is a side effect of some 
medications belonging to the antiresorptive (AR), such as bisphosphonates and 
denosumab, and antiangiogenic (AA) groups. The disease is present as an exposed 
necrotic bone in the maxilla or mandible persisting for more than 8 weeks in 
patients taking the aforementioned medical therapy but without a past history of 
radiotherapy [1, 2]. The first cases described in 2003 were thought to be a side effect 
of bisphosphonates (BP) alone and was termed bisphosphonate-related osteonecro-
sis of the jaws [3, 4]. More than 1300 publications with more than 15,000 cases have 
been published since then, with two new names indicating that medications other 
than BPs could help trigger osteonecrosis of the jaws [5].
Reports of denosumab-associated osteonecrosis began surfacing in 2010, which 
led the American Dental Association to revise the term ‘MRONJ’ to antiresorptive-
related osteonecrosis of the jaws (ARONJ) to stress the fact that other antiresorptive 
compounds could lead to osteonecrosis of the jaws [6–11].
Recently published literature has, however, demonstrated the implication of 
both antiresorptive and antiangiogenic medications in osteonecrosis of the jaws. 
It was known previously that the antiangiogenic medications could increase the 
incidence of osteonecrosis of the jaws when they were administered together with 
BP [12, 13]. New evidence indicates that antiangiogenic therapy can cause osteone-
crosis of the jaws in patients naive to BP therapy [12]. Consequently, the American 
Association of Oral and Maxillofacial Surgeons (AAOMS) published an update in 
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2014 establishing the new moniker ‘MRONJ’ to better reflect the variety of medica-
tions known to induce jaw osteonecrosis [14].
From a historical stand point, the first cases of the jaw osteonecrosis were 
described in the nineteenth century in matchmaking industry workers who were 
exposed to phosphorous compounds. The condition was known as ‘phossy jaw’, a 
painful jaw bone exposure associated with sequestration and infection. It was a very 
progressive condition with high mortality rate because of the absence of antibiotic 
therapy. The incidence of the condition “phossy jaw” decreased significantly due to 
the improvement of the working conditions in the matchmaking industry [15].
In the literature, this condition is known under several names and acronyms:
MRONJ—medication-related osteonecrosis of the jaw
BRONJ—bisphosphonate-related osteonecrosis of the jaw
BAONJ—bisphosphonate-associated osteonecrosis of the jaw
ARONJ—antiresorptive-associated osteonecrosis of the jaw
BON—bisphosphonate osteonecrosis
ONJ—osteonecrosis of the jaw [5]
1.1 Antiresorptive medicaments: bisphosphonates (BPs)
Bisphosphonates belong to a group of antiresorptive medications often used 
to treat osteoporosis. Other members of the AR group are monoclonal antibodies 
against receptor activator of nuclear factor-ĸ denosumab (RANKL), selective 
oestrogen receptor modulators, estrogens and calcitonin. Only the first two 
members, BP and denosumab, are associated with MRONJ. Unfortunately, these 
are also the most commonly utilised medications for the treatment of osteo-
porosis. BPs are in fact considered the first-choice treatment for osteoporosis 
worldwide [16, 17].
The first biological use of BP dates back to the 1960s, when etidronate was used 
to treat heterotopic ossification. Soon after, further research led to the use of BP 
in the treatment of osteoporosis [18, 19]. BPs are also used to treat non-malignant 
diseases affecting the bone tissue such as Paget’s disease of bone, fibrous dysplasia, 
cystic fibrosis, primary hyperparathyroidism and osteogenesis imperfecta [19–23].
They are also used to treat osseous malignant conditions such as metastases of 
solid tumours, malignant hypercalcemia and multiple myeloma. The literature 
shows that BPs have significant positive effects on the quality of life in cancer 
patients by reducing complications such as bone fractures, pain and serum calcium 
imbalances. Furthermore, some members of the BP family such as zolendronate 
also present antiangiogenic and antitumour features by inhibiting human endo-
thelial cell proliferation and changes in endothelial cell migration and adhesion. 
Zolendronate’s antitumour effects include induction of apoptosis as well as inhibi-
tion of cell invasion and adhesion. These aforementioned features are beneficial in 
delaying tumour growth [17, 24–29].
BPs can be divided into two groups based on the presence or absence of nitrogen 
atom in the side chain. The presence of nitrogen is related to the higher potency of 
the BP, which will clinically translate to a better antiresorptive effect and higher 
binding affinity to hydroxyapatite within bones. It is estimated that BPs have half 
lives in bone of approximately 11 years [30, 31]. Unfortunately, higher potency of 
the medication is also linked to a higher incidence of MRONJ. Bone resorption is 
achieved by two mechanisms. Non-nitrogen BPs are linked to osteoclast apoptosis. 
Nitrogen-containing BPs have a much more complex working mechanism that 
inhibits mevalonate signalling to impact osteoclastogenesis, apoptosis and cytoskel-
etal dynamics [32].
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1.2 Antiresorptive medicaments: denosumab
Denosumab is a human monoclonal antibody that inhibits receptor-activated 
nuclear factor-ĸB ligand (RANKL). Denosumab prevents the RANKL activation, 
which is crucial for osteoclast activation, function and differentiation resulting in 
decreased bone resorption and cancer-induced bone destruction. [33–37] It is avail-
able under two names: Prolia, which is used for treating osteoporosis, and Xgeva, 
which is used for treating complications in patients with bone metastases and solid 
tumours. The dosing used in the treatment of osteoporosis is 60 mg subcutaneous 
injection every 6 months. The treatment of patients with bone metastasis is 120 mg 
subcutaneous injection every 4 weeks [37]. Although the incidence of MRONJ is 
similar in patients treated with BPs and denosumab, there are some advantages 
of denosumab over bisphosphonates such as improved efficacy and better toler-
ability. Furthermore, denosumab creates no nephrotoxic effects and may be used in 
patients with renal insufficiency [36, 38, 39].
2. Antiangiogenic medications
Antiangiogenic medicines are used to treat patients with different types of tumours 
such as gastrointestinal stromal tumour, glioblastoma, hepatocellular carcinoma, hor-
mone receptor-positive breast carcinoma, mantle cell lymphoma, metastatic colorectal 
carcinoma, multiple myeloma, metastatic renal cell carcinoma,  non-squamous non-
small cell lung carcinoma, pancreatic neuroendocrine tumour, renal cell carcinoma, 
subependymal giant cell astrocytoma and soft tissue sarcoma. They are used to inhibit 
or decrease neoangiogenesis which is crucial for the expansive tumour growth. It was 
known previously that antiangiogenic medications could increase the incidence of 
osteonecrosis of the jaws when administered concurrently with BP or denosumab [12, 
40–43]. New evidence indicates that antiangiogenic therapy can also cause osteonecro-
sis of the jaws in patients naive to BP therapy [12, 41, 42, 44–49]. Many AA-associated 
cases of MRONJ were reported after the use of sunitinib and sorafenib, both of which 
are members of tyrosine kinase inhibitors [37].
3. Diagnosis of the MRONJ
In order to diagnose MRONJ, three diagnostic factors must be met:
1. Current or previous treatment with antiresorptive and/or antiangiogenic 
agents
2. Exposed bone or bone that can be probed through an intraoral or extraoral 
fistula in the maxillofacial region that has persisted for more than 8 weeks
3. No history of radiation therapy to the jaws or obvious metastatic disease to the 
jaws [1, 7, 14, 50]
Radiation therapy of the jaws must be excluded since the clinical presentation of 
the osteoradionecrosis and MRONJ may be impossible to distinguish. A diagnosis 
of osteoradionecrosis should be considered in patients with the aforementioned 
symptoms as well as a history of head or neck radiotherapy [7].
MRONJ diagnosis is established mainly via oral examination and review of 
medical history. Other more complex diagnostic tools such as imaging modalities 
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or histopathological examinations are not specific enough and should be used as 
adjunctive tools to assess the stage and extent of the disease. The initial diagnosis 
of MRONJ can be made by any dentist or physician with a basic understanding of 
MRONJ [7, 50].
Consultations with the patient’s physician are critical because many patients 
remain confused or forgetful regarding their current or previous antiresorptive 
/antiangiogenic therapy. Furthermore, cancer patients may receive a complex 
therapy consisting of different medications used at different time sequences, which 
contributes to the overall confusion.
3.1 Clinical picture of MRONJ
A defining feature of MRONJ is the exposure of necrotic bone or fistulation that 
can be probed to the osseous surface which fails to heal for more than 8 weeks. This 
clinical finding can be anticipated by mild pain and discomfort in the affected site. 
As the disease progresses, the adjacent soft tissue becomes inflamed, appearing 
erythematosus and swollen. Purulent exudate may be present as a consequence of 
a secondary infection. In the later stages of the disease, oroantral fistula, oronasal 
fistula, oral cutaneous fistula or pathological fractures may be present [1, 7, 14, 52].
3.2 Imaging
Radiographic features of MRONJ are not pathognomonic and depend on the 
stage and development of the disease.
In the early stages of the disease, zones of higher and diffused radiopacity and 
thickening of the lamina dura can be present within the affected bone. Previous 
extraction sites may demonstrate minimal or complete absence of bone healing, which 
results in radiolucent radiographic appearance with a prominent residual lamina dura.
In more developed stages of MRONJ, the exposed bone becomes colonised by 
bacteria which induce focal bone demineralisation. Radiography shows a poorly 
circumscribed mixture of radiolucent and radiopaque zones. Other osteolytic pro-
cesses with similar radiographic findings include osteomyelitis, multiple myeloma, 
metastatic disease and primary lymphoma of the bone [7, 51].
Further advancement of the disease can result in the formation of bony seques-
tra, which is visible on radiographic image as radiopaque or mottled fragments sur-
rounded by a radiolucent border. Additionally, in some cancer patients treated with 
BP, a periosteal thickening (mimicking a second layer of compact bone surrounding 
the cortical bone) and new bone formation on the Schneiderian mucous membrane 
were described [7, 51, 53].
MRI and Technetium-99m imaging modalities may be more useful in detecting 
the presence of inflammation in patients with established MRONJ [7].
Scintigraphy may show additional benefits in cancer patients undergoing intra-
venous (IV) BP therapy. There exists evidence that many of those who presented 
with an increased tracer uptake in the jaws subsequently developed necrosis, though 
further research is needed to confirm these findings [54, 55].
PET imaging has low diagnostic values in MRONJ because of a low level of 
sensitivity and accuracy [7].
3.3 Histopathology
MRONJ specimens are composed of grey coloured hard tissue and, occasion-
ally, friable soft tissue. Decalcification of the larger specimens can be prolonged 
as a result of bone sclerosis. In contrast, smaller bone specimens may have soft 
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consistency as a result of bacterial colonisation. While the necrotic fragments are 
devoid of osteocytes and osteoclasts, they may have bacterial debris adherent to 
their surfaces from bone exposure. The adjacent soft tissue consists of granulation 
tissue with or without abscess formation [7, 51].
Although infrequently, metastatic cancer was identified in bone specimens 
clinically diagnosed as MRONJ in cancer patients exposed to BP therapy. Thus, 
all the bone specimens obtained from MRONJ cancer patients either by biopsy, 
sequestrectomy or segmental osteotomy should be sent for histopathological 
analysis [56].
3.4 Microbiology
Microbiological culture assessment of exposed bone has previously failed 
to identify a definite, specific microbial aetiology behind MRONJ. The samples 
demonstrated a polymicrobial infection caused by pathogens present in the normal 
oral flora [7, 51].
4. Frequency of MRONJ
MRONJ is an uncommon disease whose frequency is generally low regard-
less of the type of antiresorptive or antiangiogenic medications administered. 
According to one study, an average general dentist can expect one new case of 
MRONJ every 62 years of his work among patients on oral BP [57]. The overall 
risk of MRONJ among patients with cancer diagnosis (primary or metastatic) 
is 0–6.7% if treated with IV BPs [58–60], 0.7–1.7% if treated with denosumab 
[58, 61, 62] and 0.2% if treated with the AA agent bevacizumab [12, 58, 63]. 
The risk range of MRONJ among patients who are exposed to both zolendronate 
(intravenous BP) and bevacizumab (antiangiogenic) is 0.9% [12]. The risk among 
patients treated for osteoporosis who are exposed to oral zolendronate alone 
is 0.02% [58, 64], while the risk for patients treated with denosumab alone is 
0.04–0.2% [58, 65, 66].
5. Risk factors of MRONJ
5.1 Risk factors connected with AR medications
• Route of administration of AR medications
Patients with intraosseous malignancies are treated intravenously with BP or 
subcutaneously with denosumab, while patients affected with osteoporosis 
can be treated with oral or intravenous BP medications or subcutaneously with 
denosumab.
Oral BPs are associated with lower occurrence risk of MRONJ than intravenous 
BPs or denosumab. The incidence of AR therapy-associated MRONJ is signifi-
cantly lower for osteoporosis patients than for cancer patients [58].
• Duration of BP therapy
The prevalence of MRONJ increases over time, from 0.5 to 0.6% after 1 year of 
therapy, 0.9 to 1.1% after 2 years and 1.3 to 1.1% after 3 years [67]. For patients 
with osteoporosis who are exposed to oral BPs, the prevalence of MRONJ 
increases over time from 0 to 0.2% after 4 years. The average duration of BP 
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therapy in patients who developed MRONJ is 4.4 years [58]. Some authors 
found that there were no significant increases in risk between the third and 
fourth years of BP therapy [59].
• Dose and potency
Zoledronic acid is considered the most potent BP medication. Its potency is 
estimated to be 10 times higher compared to ibandronate and 20 times higher 
than pamidronate [68].
5.2 Local factors
• Dental treatment
Dentoalveolar surgery with bone manipulation (tooth extraction, implant 
placement and periodontal or endodontic surgical procedures) is the most com-
mon local risk factor for patients exposed to AR/AA with MRONJ. Tooth extrac-
tion was considered a precipitating factor in 52–61% of cases of MRONJ. In 
addition, exposure to zolendronate prior to tooth extraction incurred a 16- to 
33-fold increase in risk of MRONJ [13, 69, 70]. The risk for patients treated with 
oral BPs is 0.5% or less [71, 72]. The same risk for the cancer patients treated 
with intravenous BPs is within the range of 1.6–14.8% [73, 74] or 1.7–4.7% [72] 
depending on the investigation.
Though they are considered risk factors, the exact rate of MRONJ in patients 
treated with AA/AR medications after periodontal, implant or endodontic 
surgeries is not yet certain. Anecdotal experience stipulates that they nonethe-
less demonstrate similar risks when compared to dental extractions [14].
• Dental or implant inflammation
The inflammatory processes associated with dentoalveolar surgery are 
considered a causative factor in developing MRONJ. The periodontal or 
periapical pathology were considered a risk factor for 50% of the cases of 
MRONJ [13, 14, 73, 75, 76]. Since many dental inflammatory diseases are 
treated via extraction, the exact degree to which surgical trauma or inflam-
matory changes actually contribute to the development of osteonecrosis is not 
yet clear [27].
5.3 Anatomic factors
MRONJ appears in the mandible more often than in the maxilla. Instance in the 
lower jaw is 73%, in upper jaw is 22.5% and in both jaws is 4.5% [13, 14].
Denture use increases the risk of MRONJ. This is especially true in cases of 
cancer patients with dentures exposed to ibandronate, zolendronate or pami-
dronate. These patients experience a two-fold increase in risk of osteonecrosis 
[69, 70].
5.4 Demographic risk factors
Higher prevalence of MRONJ in the female population may be associated with 
the prevalence of osteolytic conditions in women [14]. Women over 50 have a 50 
and 12% lifetime risk of developing osteoporosis and breast cancer, respectively. 
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On the other hand, men in the same age group have a 20% risk of developing 
osteoporosis and a 17% risk of prostate cancer [16].
Few studies have been conducted exploring MRONJ risk in the paediatric 
population. However, a recent survey of the literature revealed no significant rate of 
MRONJ despite the fact that a number of patients were exposed to long-lasting BP 
therapies and invasive dental treatments [77, 78].
5.5 Systemic risk factors
Corticosteroids [13, 75] and antiangiogenic [12, 13, 37, 40–43, 45–49, 69] 
medications may increase the risk of MRONJ when administered concurrently with 
a bisphosphonate.
Other comorbidities were inconsistently linked to elevated risk of developing 
MRONJ, such as anaemia, diabetes [13, 75] and the type of cancer [15, 16].
6. Staging of MRONJ
The staging system was developed primarily to guide the clinician with specific 
treatment strategies according to clinical presentation. Furthermore, it helped 
introduce homogeneity to MRONJ literature, allowing for new advancements in the 
diagnosis and treatment of the disease.
The guidelines were first published in 2006 then updated in 2009 and 2014 as a 
result of new findings relevant for treatment of the disease [2, 7, 14].
6.1 Stage 0
The initial stage includes patients exposed to AR/AA therapy with no clinical 
evidence of exposed or necrotic bone. Only non-specific symptoms are present 
which cannot be attributed to other pathological entities. Recent literature suggests 
that up to 50% of patients at stage 0 will progress to the subsequent stage.
1. Symptoms present during stage 0: odontalgia not explained by dental cause, 
dull pain in the body of the mandible, sinus pain and altered neurosensory 
function.
2. Clinical findings present during stage 0: increased tooth mobility not 
explained by periodontal disease and fistula that is not associated with endo-
dontic pathology.
3. Radiographic findings present during stage 0: alveolar bone resorption not 
associated with periodontal disease, thickening of the maxillary sinus walls, 
irregular trabecular patterns, absence of bone healing and persistent lamina 
dura in extraction sites, thickening of the lamina dura and a decrease in the 
size of the periodontal ligament space.
6.2 Stage 1
The clinical picture of stage 1 consists of exposed necrotic bone or a fistula that 
can be probed to the bone. Since there is no infection, the patients typically do not 
experience additional symptoms. Radiographic findings mentioned in the stage 0 
may also be present.
Osteonecrosis of the Craniomaxillofacial Skeleton
8
6.3 Stage 2
In the second stage, the exposed necrotic bone is infected and the patients expe-
rience pain. Second stage patients can present with abscess and fistulation as well. 
Radiographic findings mentioned in the stage 0 may also be present. The adjacent 
soft tissues may be swollen or secondarily infected.
6.4 Stage 3
All of the symptoms and clinical findings characteristic of the second stage are 
also present in the third stage: infection, pain and exposed necrotic bone or fistula-
tion that probes to bone. Furthermore, one or more of the following symptoms 
manifest as a result of disease progression beyond the anatomical borders of the 
alveolar bone:
• Exposed necrotic bone reaching the inferior border of the mandible or the floor 
of the maxillary sinuses
• Pathological fracture
• Extra-oral fistula
• Oroantral or oronasal communication
• Bone resorption extending to the inferior border of the mandible or the sinus 
floor [7, 14, 51]
7. Treatment of MRONJ
Three different types of treatment strategies have been developed for the 
MRONJ: preventive, [79, 80] medical and surgical treatments [14, 81]. Preventive 
measures are indicated for patients who are slated for AA/AR therapy or have 
undergone treatment without notable symptoms of MRONJ. The latter two treat-
ment modalities are used to treat patients with an established diagnosis of MRONJ.
7.1 Preventing MRONJ
Preventive measures are undertaken to reduce risk factors and preserve oral 
health of the patient at risk of developing MRONJ. The incidence of MRONJ can 
be reduced by up to one third if preventive measures are applied. These measures 
differ depending on the indications of the AR/AA therapy as well as the nature of 
the triggering dental treatment.
Preventive measures fundamentally rely on proper communication and col-
laboration between the oncologist, the primary care physician, the dentist and 
the patient. The healthcare professionals must inform the patient of the possibil-
ity of developing MRONJ and of the importance of oral health in its prevention. 
Prior to initiating AR/AA treatment, the patient should be referred to a dentist 
for a complete clinical and radiological oral examination. It is the dentist’s 
responsibility to evaluate the risk factors (such as dental decay, periodontal dis-
eases and ill-fitting prostheses) for each individual patient, eliminate or decrease 
the risk factors, restore oral health and maintain oral health throughout and after 
the AA/AR treatment [79, 80].
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According to some studies, only 30% of the patients taking BP are referred to 
a dentist because of a lack of AR/AA prescriber awareness. In addition, approxi-
mately 40–50% of dentists expressed a low-to-moderate level of knowledge of 
MRONJ, sometimes requesting discontinuation of medications not associated with 
osteonecrosis of the jaw [82, 83].
7.1.1 Cancer patients with AR/AA therapy
Before initiating AA/AR treatment, the oncologist should inform the patient 
about possible oral side effects and refer the patient to a dentist for comprehensive 
dental examination [79, 80]. Dentoalveolar surgery remains the major risk factor 
for developing MRONJ and extraction increases this risk, as do periodontal or 
periapical pathology [13, 69, 70]. As estimated above, pre-existing dental inflam-
matory disease is a risk factor for more than 50% of cases [13, 14, 73, 75, 76]. Thus, 
in accordance with the oncologists, the onset of the AR/AA therapy should be 
postponed until dental health is established. All extractions and dentoalveolar 
surgery should be performed and the surgical sites should be allowed to heal 
completely. Some studies advise at least 2–3 weeks of mucosal healing, while 
others recommend up to 45–60 days prior to initiation of AA/AR therapy [14, 79]. 
In the case of patients with total or partial dentures, intraoral examination for 
decubital areas should be performed. Old or ill-fitting dentures should be relined 
or replaced [69, 70].
If a cancer patient has already been exposed to AR/AA compounds, preven-
tive therapy is directed towards preventing infections and avoiding dentoalveolar 
surgery. Consequently, good oral hygiene and frequent recalls are of paramount 
importance. All infected dentition should be addressed via endodontic therapy. 
If surgery cannot be avoided, chlorhexidine (CHX) mouth wash 0.12% should 
be started 7 days before the surgical procedure 2–3 times per day and should be 
continued for the next 2 weeks after the extraction. Antibiotic treatment should 
also be initiated before the extraction and continued afterwards, though there exists 
no current consensus [79] on the type, duration, onset and route of administration 
of the antibiotic therapy [84]. Some authors also recommend deep scaling of the 
remaining teeth prior to surgical interventions [72].
Again, proper communication must be established between the oncologist, the 
dentist and the patient to reduce the rate of complications.
7.1.2 Osteoporosis patients with AR/AA therapy
The risk of MRONJ in osteoporosis patients on oral bisphosphonate therapy 
increases significantly when the duration of therapy exceeds 4 years. During the 
first 4 years of oral BP therapy, minor surgical procedures can typically be per-
formed without therapy modification. Thus, prophylactic dentoalveolar surgery is 
not critical to the degree it is in cancer patients and/or those undergoing IV AR/AA 
therapies. The patient should nonetheless be monitored regularly and given proper 
oral hygiene instruction [14, 79].
Patients who have been prescribed with a combination of BP, AA or corticosteroids 
demonstrate an additive risk of developing MRONJ [12, 13, 37, 40–43, 45–49, 69]. 
There exists much discussion in the literature regarding discontinuation (drug holi-
day) of BP therapy prior to surgical procedures. The purpose of a ‘drug holiday’ is to 
reduce the risk of MRONJ and complications with wound healing. However, suspen-
sion of BPs may increase the risk of complications including fractures. Furthermore, 
BPs have long half-lives when bound to hydroxyapatite, and the efficacy of a tempo-
rary discontinuation has been questioned. The clinician must weigh the risk of MRONJ 
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with the risk of complications in partnership with the physician who prescribed the BP 
therapy [1, 11, 14, 79, 84].
According to the guidelines from the AAOMS, a pre-operative drug holiday of 
2 months may be considered regardless of the total duration of BP therapy. This 
should also be done in partnership with the physician who has prescribed the BP 
therapy. All BP therapy should be resumed once all appropriate post-operative 
healing has occurred [14].
7.2 Medical management of MRONJ
The aim of medical management is to prevent infection of the exposed bone using 
topical or systemic antibiotics. The use of analgesics is indicated if the patient complains 
of odontalgia or dull pain located in the affected areas. Since more than 50% of patients 
diagnosed with stage 0 progress to a higher stage, frequent recalls with oral health 
instructions and preventive measure can be beneficial in the long term [54, 81, 85].
Patients presenting with stage 0 and 1 of MRONJ may be treated with medical 
modalities only. Adjunctive therapy is used to enhance healing of the exposed bone by 
decreasing inflammation, improving vascularization and stimulating bone turnover.
• Typically, the topical antibiotic of choice is chlorhexidine gluconate 0.12%
• Systemic antibiotics
The first line antibiotic is a penicillin-class antibiotic such as amoxicillin. In 
case of allergy, clindamycin, fluoroquinolones and/or metronidazole may be 
used. Currently, there exists no scientific consensus on the duration of anti-
biotic therapy, though an empiric proposition recommends a 2-week course 
for patients with a persistent stage 1 disease and 4–6 weeks course therapy for 
more advanced stages of the disease.
• Pentoxifylline and vitamin E
The combinations of these drugs have already found some success in the treat-
ment of osteoradionecrosis. Their specific mechanism of action in the treat-
ment of MRONJ is not completely understood. It is believed that their ability to 
decrease inflammation and promote vascularization can contribute to positive 
outcomes. Though the duration of the treatment has not been established, 
some studies recommend suspension of this therapy after 3 years. Patients 
with all stages of osteonecrosis may benefit from pentoxifylline and vitamin 
E. The recommended dose of pentoxifylline is 400 mg twice daily and 1000 IU 
vitamin E daily.
• Teriparatide
This drug is used primarily in the treatment of osteoporosis. It may improve 
bone remodelling by stimulating osteoblasts, increasing bone cell signalling 
and activating osteoclasts. The safety, side effects, dosing and duration of 
the therapy for MRONJ are currently not known and additional research is 
warranted.
• Hyperbaric oxygen therapy
Hyperbaric oxygen therapy is used in the treatment of osteoradionecrosis 
because of its purported beneficial effects on wound healing. This treatment 
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may help provide greater oxygenation to tissues with reduced vascular sup-
plies, accelerating wound healing and increasing bone turnover. Currently, 
the clinical utility of hyperbaric oxygen therapy in the treatment of MRONJ 
remains unclear. Higher costs and extended therapy duration could prevent 
routine use in MRONJ therapy [81].
7.3 Surgical treatment of MRONJ
Surgical treatment is typically indicated for the second and third stages of the 
disease. The degree of surgical intervention can vary from simple sequestrectomy 
to marginal or segmental osteotomies depending on disease dissemination, patient 
comorbidities, medical status and treatment expectations.
Mobile bone sequestra should always be removed regardless of the disease stage.
The term ‘marginal resection’ refers to surgical removal of the necrotic alveolar 
bone, preserving the inferior border of the mandible. On the other hand, segmental 
resection osteotomy includes removal of the inferior border of the mandible and 
results in a continuity defect. The former intervention may be used in the treat-
ment of second stage MRONJ since the disease is limited to the alveolar bone. 
Consequently, the latter is reserved for the third stage of the disease as it is charac-
terised by progression beyond the anatomical borders of the alveolar bone.
During surgical extractions or alveoplasties, the soft tissue over the bone defect 
should be sutured in multiple layers to ensure primary intention healing. Pre- and 
post-op systemic antibiotics should also be considered especially if the patient 
already has an established diagnosis of MRONJ [81].
Other adjunctive treatment modalities include platelet-rich fibrin (PRF) or other 
platelet concentrates as well as low level laser therapy. Platelet concentrates may aid 
soft tissue healing while low level laser therapy is linked to increased vascularity 
and osteoblastic differentiation, resulting in better bone healing [72, 86, 87, 89, 90].
Benefits of adjunctive treatments nonetheless remain controversial. Conflicting 
rates of healing have been reported when additional treatments were combined 
with surgical treatment compared to surgical treatments alone [86, 88–90].
8. Conclusion
MRONJ is an uncommon disease that can cause significant impairments and 
reductions in a patient’s quality of life. Additional investments should be made to 
raise awareness and increase collaboration among patients, AR/AA prescribers 
and dentists. Issues that require further investigation include the exact number of 
medications associated with MRONJ, the role of drug holidays in its prevention 
and the choice of modalities (such as antibiotics, pentoxifylline, teriparatide and 
surgery) in its treatment.
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